Domestic goose as a model for West Nile virus vaccine efficacy

Highlights ► We used domestic goose as vaccine efficacy model for WNV. ► Fowlpox vectored vaccine with WNV prM and E proteins provided the best protection. ► Domestic geese can be used in an efficacy model for vaccine protection studies. ► Parameters for protection include clinical, plasma titers, b...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2013-02, Vol.31 (7), p.1045-1050
Main Authors: Sá e Silva, Mariana, Ellis, Angela, Karaca, Kemal, Minke, Jules, Nordgren, Robert, Wu, Shixuan, Swayne, David E
Format: Article
Language:English
Subjects:
Allergy and Immunology
Animals
Antigens
Applied microbiology
Aquatic birds
Biological and medical sciences
Birds
Brain
Brain - pathology
Brain - virology
Canarypox virus
Data processing
Disease Models, Animal
E protein
Efficacy
Experiments
Fowlpox
Fowlpox virus
Fundamental and applied biological sciences. Psychology
Geese
Goose
Heart
Histocytochemistry
Histopathology
Horses
Immunization
Microbiology
Mineral oils
Miscellaneous
Mortality
Neurological diseases
Pathogenicity
Pathogens
Proteins
Studies
Vaccination - methods
Vaccine
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vector-borne diseases
Viral Load
Viremia - prevention & control
Virology
West Nile Fever - pathology
West Nile Fever - prevention & control
West Nile Fever - virology
West Nile virus
West Nile Virus Vaccines - administration & dosage
West Nile Virus Vaccines - immunology
Wildfowl
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights ► We used domestic goose as vaccine efficacy model for WNV. ► Fowlpox vectored vaccine with WNV prM and E proteins provided the best protection. ► Domestic geese can be used in an efficacy model for vaccine protection studies. ► Parameters for protection include clinical, plasma titers, brain histopathological.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2012.12.044